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ttp://dx.doi.org/10.1016/j.ajpath.2017.01.006Cutaneous squamous cell carcinoma (cSCC) is one of the most common metastatic skin cancers with
increasing incidence. We examined the roles of complement component C3 and complement factor B
(CFB) in the growth of cSCC. Analysis of cSCC cell lines (n Z 8) and normal human epidermal kerati-
nocytes (n Z 11) with real-time quantitative PCR and Western blotting revealed up-regulation of C3
and CFB expression in cSCC cells. Immunohistochemical staining revealed stronger tumor cellespeciﬁc
labeling for C3 and CFB in invasive cSCCs (n Z 71) and recessive dystrophic epidermolysis bullosae
associated cSCCs (nZ 11) than in cSCC in situ (nZ 69), actinic keratoses (nZ 63), and normal skin
(n Z 5). Signiﬁcant up-regulation of C3 and CFB mRNA expression was noted in chemically induced
mouse cSCCs, compared to benign papillomas. Knockdown of C3 and CFB expression inhibited migration
and proliferation of cSCC cells and resulted in potent inhibition of extracellular signaleregulated kinase
1/2 activation. Knockdown of C3 and CFB markedly inhibited growth of human cSCC xenograft tumors
in vivo. These results provide evidence for the roles of C3 and CFB in the development of cSCC and
identify them as biomarkers and potential therapeutic targets in this metastatic skin cancer.
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Disclosures: None declared.Cutaneous squamous cell carcinoma (cSCC) is a
keratinocyte-derived skin cancer, which is responsible for the
majority of nonmelanoma skin cancererelated mortality.1
The incidence of cSCC and its precursors [ie, actinic
keratosis (AK) and cSCC in situ (cSCCIS)] is increasing
worldwide.2 Solar UV radiation is the major risk factor
for cSCC, which typically arises in the sun-exposed areas
of skin. Other important risk factors for cSCC include
chronic cutaneous ulceration and immunosuppression.3 In
addition, chronic inﬂammation plays an important role in
cSCC progression.4
The complement system is a part of both the innate and
acquired immune systems. It can be activated via three
distinct pathways (ie, the classic, lectin, and alternative
pathways).5 C3 is a central component in the complementstigative Pathology. Published by Elsevier Inc
Y-NC-ND license (http://creativecommons.orgsystem and connects innate and acquired immunity. All
three pathways converge to activation of C3 by cleavage of
C3 to fragments C3a and C3b. This results in activation
of the terminal pathway of complement and ﬁnally to for-
mation of membrane attack complex, lysis of the target.
/licenses/by-nc-nd/4.0).
C3 and CFB in cSCCcell, onset of inﬂammation, and macrophage or B-cell
stimulation.6,7 C3a is an anaphylatoxin, and C3b binds
covalently to the surface of foreign and host cells. On host
cell surface, the C3b fragment is inactivated by different
soluble and membrane-bound inhibitors [ie, complement
factors H and I, complement receptor 1 (CD35), membrane
cofactor protein (CD46), and decay accelerating factor
(CD55)].5,8
The classic pathway of the complement system is acti-
vated by antibody/antigen complexes, and the lectin pathway
is activated by speciﬁc carbohydrates on microbial surfaces.
In the alternative pathway, constant spontaneous breakdown
of C3 takes place at low level in plasma, resulting in for-
mation of complex C3b(H2O) (alias iC3). Complement
factor B (CFB) is an important soluble component in the
alternative pathway.8 CFB binds to C3b(H2O) and is cleaved
by complement factor D, a serine proteinase, to fragments Ba
and Bb. The activated component Bb is a serine proteinase,
which remains attached to C3b and forms the alternative
pathway convertase, C3bBb. This convertase is a key
enzyme in the activation of the alternative pathway, as it
cleaves more C3 to C3b, generating an ampliﬁcation loop for
the activation of the alternative pathway.
Previous studies have shown that normal human
epidermal keratinocytes (NHEKs) produce C3 and CFB9
and that their production is regulated by inﬂammatory
cytokines.10 Inhibitors of the complement system are also
produced by epidermal keratinocytes.11,12 We have previ-
ously reported that the expression of two important
inhibitors of the alternative pathway, complement factors
H and I, is speciﬁcally up-regulated in tumor cells in
cSCCs.13,14 In addition, expression proﬁling of cSCC cell
lines has revealed elevated expression of C3 and CFB
mRNAs, as compared to NHEKs.13,14
Herein, we have examined the roles of C3 and CFB in
the development of cSCC. The results show speciﬁc
up-regulation of the expression of C3 and CFB by cSCC
cells in culture and by tumor cells in cSCCs in vivo. The
results also show that C3 and CFB regulate proliferation and
migration of cSCC cells and promote growth of cSCC
xenografts in vivo. These results identify C3 and CFB as
tumor celleassociated biomarkers for development of cSCC
and suggest them as biomarkers and potential therapeutic
targets in recurrent and metastatic cSCCs.
Materials and Methods
Ethical Issues
Collection of normal skin and cSCC tissues and the use of
archival tissue specimens was approved by the Ethics
Committee of the Hospital District of Southwest Finland.
The study was performed according to the Declaration of
Helsinki. All patients gave written and informed permission
before surgery, and the study was performed with the
authorization of Turku University Hospital (Turku,The American Journal of Pathology - ajp.amjpathol.orgFinland). The experiments with mice were performed with
the permission of the State Provincial Ofﬁce of Southern
Finland, according to institutional guidelines.
Cell Cultures
Human cSCC cell lines (n Z 8) were established from sur-
gically removed SCCs of skin.15,16 Five cSCC cell lines were
derived from primary cSCCs (UT-SCC-12A, UT-SCC-91,
UT-SCC-105, UT-SCC-111, and UT-SCC-118) and three
from metastatic cSCCs (UT-SCC-7, UT-SCC-59A, and UT-
SCC-115). Cell lines were authenticated by STR DNA
proﬁling.16 The spontaneously immortalized nontumorigenic
human keratinocyteederived cell line HaCaT16,17 and three
Ha-rasetransformed tumorigenic HaCaT cell lines (A5, II-4,
and RT3)18 were kindly provided by Dr. Norbert Fusenig
(German Cancer Research Center, Heidelberg, Germany).
A5 cells form benign, II-4 cells low-grade malignant, and
RT3 cells high-grade malignant tumors in nude mice
in vivo.19 NHEKs were cultured from nonmalignant skin of
patients (n Z 10) undergoing surgery for mammoplasty at
Turku University Hospital. In addition, primary human
epidermal keratinocytes (NHEK-PC) were acquired from
PromoCell (Heidelberg, Germany). Cells were cultured, as
previously described.13,14 To study the effect of inﬂamma-
tory cytokines, cultures were maintained in serum-free Dul-
becco’s modiﬁed Eagle’s medium for 24 hours, and then
treated with 100 U/mL interferon (IFN)-g (Promega, Madi-
son, WI) or 20 ng/mL tumor necrosis factor (TNF)-a (Sigma,
St. Louis, MO) for 24 hours.
Tissue RNA
Normal human skin samples (n Z 10) were obtained from
the upper arm of healthy volunteers or during mammoplasty
operation in Turku University Hospital. Primary cSCC
(n Z 6) samples were collected from surgically removed
tumors in Turku University Hospital.15 Total RNA was
isolated from the tissue samples and analyzed by real-
time quantitative RT-PCR (RT-qPCR), as previously
described.20
RT-qPCR
The cell cultures were incubated in serum-free media for
24 hours before RNA isolation. Total RNA extraction
was performed by using RNeasy Mini Kit (Qiagen, Chat-
worth, CA). cDNA was synthesized using 1 mg of RNA
treated with RQ1 DNase (M610A; Promega Corp., Madi-
son, WI), random primers (C118A; Promega), M-MLV
Reverse Transcriptase (M531A; Promega), and RNase H
minus polymerase (M368B; Promega). The mRNA levels
for C3, CFB, and b-actin were determined by RT-qPCR
using speciﬁc primers and dual-labeled ﬂuorescent probes
designed by RealTimeDesign software (Biosearch Tech-
nologies, Petaluma, CA) (Table 1).20 Murine functional1187
Table 1 Primer and Probe Sequences Used for Quantitation of the mRNAs of Human C3, CFB, and b-Actin, and Murine C3, CFB Variant 1,
CFB Variant 2, and b-Actin with RT-qPCR
Gene Primer/probe Sequence
Human C3 Forward primer 50-GCCAAGACGAAGAGAA-30
Reverse primer 50-GGCACCCAAAGACAAC-30
Probe 50-CCAGAAACAATGCCAGGACCTCGG-30
Human CFB Forward primer 50-CTGTGGCATGGTTTGG-30
Reverse primer 50-GGGCGAATGACTGAGAT-30
Probe 50-CACAGGAAGGGTACCGATTACCACA-30
Human ACTB Forward primer 50-TCACCCACACTGTGCCCATCTACGC-30
Reverse primer 50-CAGCGGAACCGCTCATTGCCAATGG-30
Probe 50-ATGCCCTCCCCCATGCCATCCTGCGT-30
Murine C3 Forward primer 50-GACGCCACTATGTCCATCCT-30
Reverse primer 50-CCAGCAGTTCCAGGTCCTTTG-30
Probe 50-CATCTCCATGATGACTGGCTTTGCTCC-30
Murine Cfb variant 1 Forward primer 50-GGATGTCAAAGCTCTGTTTGTATC-30
Reverse primer 50-CTTTCTTGTCCCCATTCTTGATGTA-30
Probe 50-TGAGCAAGGGAAGAGCCTGACTC-30
Murine Cfb variant 2 Forward primer 50-GGATGTCAAAGCTCTGTTTGTATC-30
Reverse primer 50-ACTGGCTTGTCCCCATTCTTGATGT-30
Probe 50-TGAGCAAGGGAAGAGCCTGACTC-30
Murine Actb Forward primer 50-TGGCTCCTAGCACCATGAAGA-30
Reverse primer 50-GTGGACAGTGAGGCCAGGAT-30
Probe 50-CAAGATCATTGCTCCTCCTGAGCGCA-30
ACTB, b-actin; CFB, complement factor B; RT-qPCR, real-time quantitative RT-PCR.
Riihilä et alCFB consists of two isoforms that are coded by different
variants, variants 1 and 2. C3 and CFB mRNA levels were
corrected for levels of b-actin mRNA. In each measurement,
range of the threshold cycle values was <5% of the mean
and the samples were analyzed in duplicate.
Western Blot Analysis
Production of C3 and CFB by NHEKs, cSCC, and HaCaT
cell lines was determined by Western blot analysis of
aliquots of total cell lysates or conditioned media under
nonreducing conditions using speciﬁc polyclonal goat
anti-C3 and anti-CFB antibodies (both from Calbiochem,
San Diego, CA). Equal protein loading was conﬁrmed with
b-actin antibody (A 1978; Sigma-Aldrich, St. Louis, MO).14
Tissue Samples and Immunohistochemistry
Altogether, 221 archival formalin-ﬁxed, parafﬁn-embedded
tissue samples from sporadic, UV-induced cSCC (n Z 71;
mean age, 79 years; range, 45 to 102 years), cSCCIS
(Bowen’s disease; nZ 69; mean age, 79 years; range, 59 to
95 years), AK (nZ 63; mean age, 78 years; range, 58 to 95
years), normal skin (nZ 5) were obtained from the archives
of the Department of Pathology, Turku University Hospital.
In addition, recessive dystrophic epidermolysis bullosa
(RDEB)eassociated cSCC tissue samples (n Z 11; mean
age, 33 years; range, 12 to 56 years) were used.21,22 Human
tissue samples were assembled into tissue microarray
blocks, as previously described,23 to enhance comparability.
One representative cSCC sample was also analyzed as a1188whole tissue section. The sections were stained with goat
polyclonal antibodies for C3 and CFB (both from Calbio-
chem) diluted in phosphate-buffered saline containing 1.5%
horse serum. Immunostaining was performed with
avidinebiotineperoxidase complex technique (Vecta
stain ABC Kit; Vector Laboratories, Inc., Burlingame, CA)
in combination with diaminobenzidine and Mayer’s
hematoxylin (Sigma-Aldrich Chemie GmbH, Steinheim,
Germany) as a counterstain.21 Negative control staining was
performed by replacing the primary antibody with
phosphate-buffered saline. The immunostainings of C3 and
CFB were scored as negative (-), weak (þ), moderate (þþ),
or strong (þþþ), on the basis of the intensity of cell surface
and cytoplasmic staining, by two independent observers
(P.R. and M.K.). Whole slides of cSCC samples were
digitally scanned using a Pannoramic 250 Slide Scanner
(3DHistech, Budapest, Hungary).
siRNA Knockdown of C3 and CFB Expression
For siRNA knockdown of C3 and CFB, cSCC cells were
grown to 50% conﬂuency and transfected with siRNA tar-
geting C3 (Hs_C3_8, 50-ACGGTGGTGGCTATGGCTCTA-
30; Hs_C3_6, 50-CACGGAGAAGCGAATGGACAA-30);
Hs_C3_7 (50-TAGGAACACCCTCATCATCTA-30); or
CFB (Hs_CFB_1, 50-CAGCGGCGAACGTGTCAGGAA-
30; Hs_CFB_3, 50-CCAGATGACGTCCCTCCTGAA-30),
or with negative control siRNA (75 nmol/L; all from
Qiagen, New Delhi, India) using siLentFect Lipid Reagent
(Bio-Rad Laboratories, Hercules, CA), as previously
described.23 Cells were harvested at 72 hours, and the functionajp.amjpathol.org - The American Journal of Pathology
C3 and CFB in cSCCof C3 and CFB siRNAs was veriﬁed by Western blot
analysis. b-Actin served as loading control, and Western blot
band intensities were quantiﬁed by ImageJ software version
1.47v (NIH, Bethesda, MD; http://imagej.nih.gov/ij).24Cell Proliferation Assays
cSCC cell cultures were transfected with 75 nmol/L C3
siRNA, CFB siRNA, or negative control siRNA. Cells (1.0
104 cells/well) were seeded onto 96-well plates 24 hours after
transfection. The number of viable cells was determined with
WST-1 cell proliferation assay (Roche Diagnostics,
Mannheim, Germany) at 0, 24, 48, and 72 hours. The exper-
iment was performed with ﬁve to eight parallel wells in every
time point with cSCC cell lines UT-SCC-12A and UT-SCC-7
for C3 siRNA, and with cSCC cell lines UT-SCC-12A and
UT-SCC-91 for CFB siRNA. Activation of extracellular
signaleregulated kinase (ERK) 1/2 was analyzed by Western
blotting of the cell lysates with speciﬁc rabbit antibody for
p44/42 mitogen-activated protein kinase (ERK1/2; 9102) and
phospho-p44/42mitogen-activated protein kinase (p-ERK1/2;
9101), both from Cell Signaling Technology (Beverly, MA).Cell Migration Assays
cSCC cell cultures were transfected with 75 nmol/L C3
siRNAs, CFB siRNAs, or control siRNA and incubated in
complete growth medium for 24 hours to reach conﬂuency.
Cell division was inhibited with 1 mmol/L hydroxyurea
(Sigma Aldrich) treatment in Dulbecco’s modiﬁed Eagle’s
medium with 10% fetal calf serum for 16 hours. A scratch in
the cell monolayer was generated with pipette tip and the
incubation of cells was continued in Dulbecco’s modiﬁed
Eagle’s medium with 1% fetal calf serum and 0.5 mmol/L
hydroxyurea for 8 and 24 hours. Migration was analyzed with
Olympus IX70 inverted microscope (Olympus Optical Co.,
Tokyo, Japan) The cell-free areas were measured from two to
six areas in one well with ImageJ software version 1.47v24 in
three parallel wells with two cSCC cell lines (UT-SCC-105
and UT-SCC-91).Human cSCC Xenografts
Human cSCC xenografts were established, as described pre-
viously.14,25 UT-SCC-7 cell cultures were transfectedwith C3
siRNA_7 or control siRNA (nZ 8 in both groups). Similarly,
UT-SCC-91 cell cultureswere transfectedwithCFBsiRNA_1
or control siRNA. After 72 hours in C3 siRNA experiment,
cSCC cells (5  106) and in CFB siRNA experiment, cSCC
cells (7  106) in 100 mL of phosphate-buffered saline were
injected s.c. in the backof severe combined immunodeﬁciency
(SCID/SCID) female mice (CB17/Icr-Prkdcscid/IcrIcoCrl)
(nZ 7 to 8 for each group) (Charles River Laboratorie). The
size of tumors was measured twice a week, and tumor volume
was calculated with the formula: VZ (length  width2)/2.26The American Journal of Pathology - ajp.amjpathol.orgTumors were harvested after 18 days for histologic anal-
ysis and immunohistochemistry, as previously described.14
Proliferating cells were detected with monoclonal human
Ki-67 antibody (MIB-1; Dako, Glostrup, Denmark) and
Mayer’s hematoxylin was used as counterstain. The relative
number of Ki-67epositive cells was determined by counting
400 to 1000 cells from all sections at 20 magniﬁcation
using ImageJ software version 1.47v.24
Mouse Skin Chemical Carcinogenesis
Mouse skin carcinogenesis was induced in FVB/N HanHsd
mice (maintained at the Laboratory Animal Center, Uni-
versity of Oulu, Oulu, Finland), as previously described.27
Skin tumor formation was induced ﬁrst by topical admin-
istration of a single dose of 7,12-dimethylbenz[a]anthracene
(100 mg; DMBA; Sigma-Aldrich) in 100 mL acetone on the
shaved dorsal skin and then followed by treatment of skin
with 5 mg 12-O-Tetradecanoylphorbol-13-acetate (TPA) in
100 mL acetone once a week for 20 weeks. The appearance
of tumors was examined weekly and mice were sacriﬁced at
week 32 or earlier if invasive carcinomas appeared, tumor
size exceeded 10 mm, or tumor load was excessive. DMBA-
TPAeinduced cSCC (n Z 27), benign papillomas (n Z
17), hyperplastic TPA-treated (nZ 6), acetone-treated (nZ
2) and untreated normal (n Z 8) skin samples were har-
vested and processed for histologic examination and RNA
extraction, as previously described.27 The skin tissue sam-
ples were classiﬁed as hyperplasia, or well, moderately, or
poorly differentiated SCC on the basis of analysis of he-
matoxylin and eosinestained sections. Outliers have been
deleted during statistical analysis.
Statistical Analysis
The statistical analyses were performed with the IBM SPSS
Statistics software version 22.0 (IBM Corp., Armonk, New
York, NY) to determine the signiﬁcance of differences be-
tween two sample groups for RT-qPCR, Ki-67epositive
staining, and proliferation and migration assays by Mann-
Whitney U test or t-test. Comparison of immunohistochem-
ical (IHC) staining intensity was performed with c2 test.
Results
Expression of C3 and CFB Is Up-Regulated in cSCC Cells
In our previous studies, marked up-regulation of the
expression of C3 and CFB mRNA was noted in cSCC cell
lines by microarray-based expression proﬁling and RNA
sequencingebased whole transcriptome expression
proﬁling.13,14 Herein, the mRNA levels of C3 and CFB were
measured by RT-qPCR. The mean expression levels of C3
and CFB mRNAs were signiﬁcantly higher in cSCC cells
(n Z 8), as compared to NHEKs (n Z 11) (Figure 1A). No
difference was noted in the expression levels of C3 mRNA1189
Figure 1 Expression of C3 and complement factor B (CFB) is up-regulated in cutaneous squamous cell carcinoma (cSCC) cells.A: C3 and CFBmRNA levels in normal
human epidermal keratinocytes (NHEKs), primary, andmetastatic cSCC cell lines were determined by real-time quantitative PCR (RT-qPCR) and the levelswere corrected
for b-actin mRNA levels in the same samples. B: The levels of C3 (185 kDa) and CFB (86 kDa) in NHEKs and cSCC cell lines were determined by Western blotting of
conditioned media under nonreducing conditions. b-Actin in cell lysates was determined as a loading control. Migration positions of molecular weight markers are
shown on the left. C3 and CFB levels were quantitated densitometrically and corrected for b-actin levels in the corresponding cell lysates. Values are shown below the
Westernblots relative to levels inNHEK63 cells (1.00).C: Levels of C3andCFBmRNA innormal skinand cSCC sampleswere analyzedbyRT-qPCR andcorrected forb-actin
mRNA levels in the same samples. Horizontal bars indicate the mean values for each group. nZ 11 (A, NHEKs, and C, normal skin); nZ 5 (A, primary cSCC cell lines);
nZ 3 (A, metastatic cSCC cell lines); nZ 4 (B, NHEKs); nZ 8 (B, cSCC cell lines); nZ 6 (C, cSCC samples). *P < 0.05, ***P < 0.001 (Mann-Whitney U test).
Riihilä et albetween primary and metastatic cSCC cell lines. However,
the expression level of CFB mRNA was higher in primary
cSCC cell lines than in metastatic cSCC cell lines
(Figure 1A). Using Western blot analysis, C3 (185 kDa) was
detected in conditioned media of cSCC cell lines and NHEKs
(nZ 4), and the production of C3 was higher in ﬁve of eight
cSCC cell lines than in NHEKs (Figure 1B). CFB (86 kDa)
was detected in the conditioned media of most cSCC cell
lines and the production of CFB was higher in six of eight
cSCC cell lines than in NHEKs (Figure 1B). Elevated levels
of C3 and CFB mRNAs were also detected in RNA from
cSCC tumor tissue (n Z 6), as compared with RNA from
normal skin (n Z 11) (Figure 1C).
Expression of C3 and CFB by Tumor Cells in cSCCs
in Vivo
The expression of C3 andCFB in vivowas further analyzed by
IHC using tissue microarrays consisting of a large panel of
tissue samples representing different stages of epidermal1190carcinogenesis [namely, normal skin (n Z 5), premalignant
precursor lesion, AK (n Z 63), carcinoma in situ (cSCCIS;
nZ 69), and cSCC (nZ 71)]. For comparison, tissue samples
of an aggressive formof cSCC,RDEBSCC (nZ11)were also
included. Prominent tumor cellespeciﬁc staining intensity for
C3 was noted in cSCCs (Figure 2, A and B). The staining for
C3 was either cytoplasmic or on cell surface (Figure 2C). In
addition, strong staining intensity for C3 was noted in tumor
cells in RDEBSCC samples (Figure 2D). The staining for C3
was clearly weaker in cSCCIS and AK tissue samples than in
cSCC tissue sections (Figure 2, F andG). Tumor cellespeciﬁc
immunostaining for C3 was also noted ex vivo in xenografts
establishedwith human cSCCcells (UT-SCC-7) in SCIDmice
(Figure 2H). Semiquantitative analysis of IHC staining
revealed strong (þþþ) or moderate (þþ) staining in most
tissue sections in cSCCandRDEBSCCgroups (Figure 2I).On
the other hand, in AK and cSCCIS groups, the proportion of
tissue sections with negative (-) and weak (þ) staining was
signiﬁcantly higher than in cSCC or RDEBSCC samples. In
normal skin group, staining of tissue samples for C3 wasajp.amjpathol.org - The American Journal of Pathology
Figure 2 Expression of C3 by tumor cells in cutaneous squamous cell carcinoma (cSCC). AeH: Sections of tissue microarray blocks containing cSCC,
aggressive forms of cSCC, recessive dystrophic epidermolysis bullosaeassociated cSCCs (RDEBSCC), normal skin, premalignant lesions [actinic keratosis (AK)],
and cSCC in situ (cSCCIS), were stained with C3 antibody. In addition, sections of xenografts established in severe combined immunodeﬁciency mice with cSCC
cell line (UT-SCC-7) ex vivo were stained with C3 antibody. The staining is moderate (þþ) or strong (þþþ) in moderately differentiated (Grade 2) cSCC (A) or
well-differentiated (Grade 1) cSCC (B) and in RDEBSCC (D). C: The staining for C3 is seen in tumor cell cytoplasm (white arrow) or on cell surface (black
arrow). E: Epidermal staining for C3 is absent () in normal skin. In premalignant lesions (AK; F) and in cSCCIS (G) the staining is weak or moderate. H: Tumor
cells in cSCC xenografts stain strongly for C3. I: Semiquantitative analysis of C3 staining in normal skin, AK, cSCCIS, cSCC, and RDEBSCC. Tumor cellespeciﬁc
immunostaining intensities of each section were scored as negative (), weak (þ), moderate (þþ), and strong (þþþ). nZ 68 (cSCC); nZ 11 (RDEBSCC);
n Z 5 (normal skin); n Z 63 (AK); n Z 59 (cSCCIS). *P < 0.05, **P < 0.01, and ***P < 0.001 (c2 test). Scale bar Z 100 mm (AeH).
C3 and CFB in cSCCnegative ormoderate (Figure 2, E and I). Expression ofC3was
also analyzed in a representative whole tissue section of cSCC
by IHC. Herein, more abundant staining for C3 was seen on
surface or in the cytoplasmof tumor cells inwell-differentiated
parts of the cSCC, whereas in the adjacent AK the speciﬁc
staining was weaker (Supplemental Figure S1).
Cytoplasmic staining for CFB was detected in tumor cells
in cSCC tissue samples (Figure 3C) and was classiﬁed
mainly as moderate or strong (Figure 3, A and B). As forFigure 3 Expression of complement factor B (CFB) by tumor cells in cutaneous
containing cSCC, aggressive forms of cSCC, recessive dystrophic epidermolysis bull
were stained with CFB antibody. In addition, xenografts established in SCID mice
tumor cells for CFB was moderate (þþ) in well-differentiated (Grade 1) cSCC (A) an
for CFB was detected in cytoplasm of tumor cells. D: Strong staining for CFB
In premalignant lesions (AK; F) and cSCCIS (G) the staining is weak (þ). H: Tumo
analysis of CFB staining in normal skin, AK, cSCCIS, cSCC, and RDEBSCC. The stainin
the speciﬁc staining intensity of tumor cells. n Z 71 (cSCC); n Z 10 (RDEBSC
**P < 0.01, ***P < 0.001 (c2 test). Scale bar Z 100 mm (AeH).
The American Journal of Pathology - ajp.amjpathol.orgC3, the staining intensity for CFB was stronger in
RDEBSCC tissue sections (Figure 3D). In premalignant
lesions (AK) and in cSCCIS, staining for CFB was negative
or weak in most tissue samples (Figure 3, F and G). Normal
skin was negative or stained weakly for CFB (Figure 3E).
No correlation was detected between staining for CFB and
the degree of inﬂammation. Tumor cellespeciﬁc immuno-
staining for CFB was also noted ex vivo in tissue sections of
the xenograft tumors established with human cSCC cellssquamous cell carcinoma (cSCC). AeH: Sections of tissue microarray blocks
osaeassociated cSCCs (RDEBSCC), normal skin, premalignant AK, and cSCCIS
with cSCC cell line (UT-SCC-91) ex vivo were stained for CFB. The staining of
d strong (þþþ) in poorly differentiated (Grade 3) (B) cSCC. C: The staining
is detected in RDEBSCC. E: In normal skin the staining is negative ().
r cells in cSCC xenografts stain strongly (þþþ) for CFB. I: Semiquantitative
g was scored negative (), weak (þ), moderate (þþ), or strong (þþþ) by
C); n Z 5 (normal skin); n Z 56 (premalignant AK); n Z 69 (cSCCIS).
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Figure 4 Expression of C3 and complement factor B (CFB) in chemically induced mouse cutaneous squamous cell carcinoma (cSCC). The mRNA levels for
mouse C3, CFB variant 1, and CFB variant 2 in mouse normal skin, acetone-treated skin, TPA-treated hyperplastic skin, papilloma, and DMBA-TPAeinduced cSCC
were determined by real-time quantitative RT-PCR and corrected for the levels of b-actin mRNA in the same samples. Horizontal bars in box plots indicate
median, boxes indicate interquartile range, and whiskers indicate lowest and highest values within 1.5 times the interquartile range for each group. Outliers
have been deleted. A: The mRNA levels for mouse C3 in mouse normal skin, acetone-treated skin, TPA-treated hyperplastic skin, papilloma, and DMBA-
TPAeinduced cSCC. The expression of C3 mRNA in mouse cSCC is signiﬁcantly higher than in benign papilloma. B: The mRNA levels for mouse CFB variant 1 in
mouse normal skin, acetone-treated skin, TPA-treated hyperplastic skin, papilloma, and DMBA-TPAeinduced cSCC. The expression of CFB variant 1 mRNA is
signiﬁcantly higher in cSCC than in papilloma. C: The mRNA levels of CFB variant 2 in mouse normal skin, acetone-treated skin, TPA-treated hyperplastic skin,
papilloma, and DMBA-TPAeinduced cSCC. The expression of CFB variant 2 mRNA is signiﬁcantly higher in cSCC than in papilloma. n Z 8 (A, normal skin);
nZ 2 (AeC, acetone-treated skin); nZ 6 (AeC, TPA-treated hyperplastic skin); nZ 16 (A and C, papilloma); nZ 25 (A and B, DMBA-TPAeinduced cSCC);
n Z 7 (B and C, normal skin); n Z 17 (B, papilloma); n Z 23 (C, DMBA-TPAeinduced cSCC). ***P < 0.001.
Riihilä et al(UT-SCC-91) in SCID mice (Figure 3H). Semiquantitative
analysis revealed strong or moderate staining for CFB in
most tissue sections in cSCC and RDEBSCC groups
(Figure 3I). In comparison, the proportion of negative (-)
and weak (þ) staining for CFB was signiﬁcantly higher in
AK and cSCCIS groups than in cSCC or RDEBSCC tissues.
In normal skin group, staining of tissue samples for CFB
was weak or negative (Figure 3, E and I). Expression of
CFB was also analyzed in a whole cSCC tissue section by
IHC. Herein, the staining was stronger on surface or in the
cytoplasm of tumor cells in well-differentiated parts of the
cSCC, whereas in the adjacent tissue representing AK the
staining was weak (Supplemental Figure S1).Figure 5 Regulation of C3 and complement factor B (CFB) expression in HaCa
(cSCC) cells. A: The presence of C3/C3b (193/184 kDa), and C3 cleavage products
CFB (86 kDa) in medium samples of NHEK-PC, HaCaT, and Ha-rasetransformed HaC
nonreducing conditions. Cell lysate b-actin was determined as loading control. M
levels of C3 and CFB were quantitated densitometrically and corrected for b-actin l
blots and relative to the levels in NHEK-PC cells (1.0). B: Primary cSCC cell lines
20 ng/mL tumor necrosis factor (TNF)-a for 24 hours. Levels of C3 and CFB mRNA
of b-actin mRNA in the same samples. Data are expressed as means  SD (B). *
1192Expression of C3 and CFB in Chemically Induced Mouse
cSCC
To further examine the expression ofC3andCFBduring cSCC
growth, mouse model of chemically induced cSCC was
used.15,27 Total RNA samples from normal skin (n Z 8),
acetone-treated skin (n Z 2), TPA-treated hyperplastic skin
(n Z 6), papilloma (n Z 17), and DMBA-TPAeinduced
cSCC (n Z 25) were analyzed by RT-qPCR for the
mRNA levels ofC3 and twomurine variants ofCFB, variants 1
and 2.The results showed that the expression ofmRNAs forC3
and CFB variants 1 and 2 was signiﬁcantly higher in mouse
cSCCs than in nonmalignant papilloma tissues (Figure 4).T and Ha-rasetransformed HaCaTs and cutaneous squamous cell carcinoma
iC3b (182 kDa), C3c (142 kDa), C3bþa027 (102 kDa), C3a067 (67 kDa), and
aT cell cultures (A5, II-4, and RT3) was analyzed by Western blotting under
igration positions of molecular weight markers are shown on the left. The
evels in the corresponding cell lysates. Values are shown below the Western
(UT-SCC-105 and -118) were treated with 100 U/mL interferon (IFN)-g and
were measured by real-time quantitative RT-PCR and corrected for the levels
P < 0.05, **P < 0.01 (t-test). Ctr, control.
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Figure 6 Knockdown of C3 and complement
factor B (CFB) inhibits proliferation and migration
of cutaneous squamous cell carcinoma cells (cSCC).
A: C3 and CFB were knocked down by speciﬁc siRNAs
(C3 siRNA_8 or CFB siRNA_1; 75 nmol/L) in primary
cSCC cells (UT-SCC-12A) and parallel cultures were
transfected with control siRNA. Cell lysates were
analyzed for the levels of C3 and CFB with Western
blotting 72 hours after transfections with siRNA. The
levels were quantitated densitometrically and cor-
rected for b-actin levels in the same sample. Values
are shown below the Western blots relative to the
levels in control siRNAetransfected cultures (1.00).
B: cSCC cells (UT-SCC-12A) were transfected with 75
nmol/L control siRNA, C3 siRNA_8, or CFB siRNA_1.
The number of viable cells was determined at 72
hours using WST-1 assay. C: cSCC cell (UT-SCC-12A)
lysates were analyzed for the levels of phosphory-
lated extracellular signaleregulated kinase-1/2
(p-ERK1/2) and total ERK1/2 by Western blotting
48hours after siRNA transfection. Levels of p-ERK1/2
were quantitated by densitometry and corrected for
the levels of total ERK1/2 in the same samples. Values
are shown below the Western blots relative to the
levels in control siRNA transfected cultures (1.00).
D: cSCC cells (UT-SCC-105) were transfected with
75nmol/L control siRNA, C3 siRNA_8, or CFB siRNA_1
and incubated for 24 hours. The cultures were then
treated with 1 mmol/L hydroxyurea for 16 hours to
inhibit cell proliferation. A scratch was generated in
the cell monolayer by pipette tip and incubation was
continued in Dulbecco’s modiﬁed Eagle’s medium
with 1% fetal calf serum and 0.5mmol/L hydroxyurea
for 8 and 24 hours. Quantitation of the relative
migration rate for C3 and CFB siRNA transfected
cultures. E: Representative images at time points
0 and 24 hours are shown. Data are expressed as
means SEM (D).nZ 7 to 8 parallel wells (B);nZ3
(D). **P < 0.01, ***P < 0.001 (t-test).
C3 and CFB in cSCCExpression of C3 and CFB in Tumorigenic
Ha-raseTransformed HaCaT Cells
To further investigate the signiﬁcance of C3 and CFB in
the epidermal carcinogenesis, the expression of C3 and
CFB was determined in immortalized nontumorigenic
keratinocyte-derived cell line (HaCaT) lacking functional
p53, and in three Ha-rasetransformed tumorigenic HaCaT-
derived cell lines (A5, II-4, and RT3).19 Production of C3
and CFB was elevated in invasive tumorigenic cell line II-4
and was highest in metastatic cell line RT3 (Figure 5A). As
shown previously,13,14 the C3 inhibitors complement factors
H and I are expressed by cSCC cells. The function of these
inhibitors is seen by the presence of C3 cleavage fragments in
the media of RT3 cells (Figure 5A).
Regulation of C3 and CFB Expression in cSCC Cell Lines
To examine the regulation of C3 and CFB expression, cSCC
cell line cultures were treated with inﬂammatory cytokines
IFN-g or TNF-a. In primary cSCC cell line (UT-SCC-105),
the mRNA expression of C3 was up-regulated by IFN-gThe American Journal of Pathology - ajp.amjpathol.org(Figure 5B). The expression of CFBmRNAwas up-regulated
by IFN-g and TNF-a in another primary cSCC cell line
(UT-SCC-118) (Figure 5B).C3 and CFB Regulate cSCC Cell Proliferation and
Migration
To examine the functional roles of C3 andCFB in cSCC cells,
their expression was silenced by speciﬁc siRNAs (Figure 6A
and Supplemental Figure S2A). Signiﬁcant reduction in the
number of viable cSCC cells was noted 72 hours after
transfection with C3 siRNAs and CFB siRNAs (Figure 6B
and Supplemental Figure S2B). The inhibitory effect of C3
and CFB knockdown on cSCC cell proliferation was pre-
ceded by inhibition of ERK1/2 activation noted 48 hours after
transfection with speciﬁc siRNAs (Figure 6C and
Supplemental Figure S2C). Moreover, the migration rate of
cSCC cells was signiﬁcantly reduced after C3 or CFB
knockdown (Figure 6, D and E, and Supplemental Figure S2,
D and E). Similar results on cell migration were obtained with
another cell line (UT-SCC-91; data not shown).1193
Figure 7 Knockdown of C3 suppresses growth of cutaneous squamous
cell carcinoma (cSCC) in vivo. A: Metastatic cSCC cells (UT-SCC-7) were
transfected with C3 siRNA_7 or control siRNA and incubated for 72 hours.
Cells (5  106) were injected s.c. in the back of SCID mice and the size of
tumors was measured twice a week. t-Test was used. B: The xenograft
tumors were harvested after 18 days and histologic analysis performed in
tumor sections stained with hematoxylin and eosin (H&E). Proliferating
cells in xenografts were detected by immunohistochemistry for Ki-67 with
Mayer’s hematoxylin as counterstain. Representative staining from each
group are shown. C: The relative number of Ki-67epositive cells was
determined by counting 400 to 1000 cells at 20 magniﬁcation in all
tumor sections using digital imaging. Horizontal bars indicate the mean
values for each group (Mann-Whitney U test). Data are expressed as
means  SEM (A). n Z 8 (A and C). *P < 0.05, ***P < 0.001. Scale
bar Z 200 mm (B).
Riihilä et alC3 and CFB Regulate cSCC Growth in Vivo
The roles of C3 and CFB on cSCC growth was examined
in vivo in a xenograft model. Cultures of metastatic cSCC
cells (UT-SCC-7) were transfected with C3 and control
siRNA in parallel, incubated for 72 hours, and injected
(5  106) s.c. into the back of SCID/SCID mice. Determi-
nation of the size of xenografts showed that the growth of
cSCC xenograft tumors with C3 knockdown was signiﬁ-
cantly reduced, as compared to control siRNA tumors
(Figure 7A). Moreover, histologic analysis of xenografts
harvested 18 days after implantation showed that the tumors
in C3 knockdown group were less cellular than the control
tumors (Figure 7B). In addition, the relative number of
proliferating Ki-67epositive cells was lower in C3 knock-
down tumors (Figure 7, B and C).
The role of CFB on cSCC growth in vivo was similarly
examined in xenograft model, as above. Primary cSCC cells1194(UT-SCC-91) were cultured and transfected with CFB and
control siRNA in parallel, and transfected cells (7  106)
were injected s.c. into the back of SCID/SCID mice. The
growth of cSCC xenograft tumors established with cSCC
cells with CFB knockdown was signiﬁcantly reduced, as
compared to control tumors established with control
siRNAetransfected cSCC cells (Figure 8A). Histologic
analysis of the xenografts showed that the morphology of
CFB knockdown tumors was clearly different from control
xenograft tumors (Figure 8B). The tumor cells in CFB
knockdown xenografts were arranged into tight groups,
whereas in control siRNA tumors the tumor cells were
bigger and formed larger groups. The stromal compartment
of CFB knockdown tumors was also less cellular than the
stroma of control siRNA xenografts (Figure 8B). In addi-
tion, the relative number of proliferating Ki-67epositive
cells was signiﬁcantly reduced in CFB knockdown
tumors (Figure 8C).ajp.amjpathol.org - The American Journal of Pathology
Figure 8 Knockdown of complement factor B (CFB) suppresses growth of
cutaneous squamous cell carcinoma (cSCC) in vivo. A: Primary cSCC cells (UT-
SCC-91) were transfected with CFB siRNA_1 or control siRNA and incubated for
72 hours. Cells (7 106) were injected s.c. in the back of SCIDmice and the size
of tumors was measured twice a week. B: The xenograft tumors were harvested
after 18 days and histologic analysis of the tumor sections stained with he-
matoxylin and eosin (H&E) was performed. Proliferating cells in xenografts
were detected by immunohistochemistry for Ki-67 with Mayer’s hematoxylin as
counterstain. Representative staining from each group are shown. C: The
relative number of Ki-67epositive cells was determined by counting 400 to
1000 cells at 20 magniﬁcation in all tumor sections using digital imaging.
Horizontal bars indicate themean values for each group, control siRNA and CFB
siRNA (Mann-Whitney U test). Data are expressed as means SEM (A). nZ 8
(A and C, CFB siRNA_1); n Z 7 (A and C, control siRNA). **P < 0.01,
***P < 0.001. Scale barZ 200 mm (B).
C3 and CFB in cSCCDiscussion
The results of this study demonstrate elevated expression of
C3 and CFB mRNA in cSCC cells in culture and in vivo
compared to NHEKs and normal intact skin, respectively. In
addition, increased production of C3 and CFB by cSCC
cells in culture was noted (Figure 1). Analysis of tissue
microarrays consisting of a large panel of cSCC, cSCCIS,
AK, and normal skin by IHC revealed speciﬁc cytoplasmic
staining for C3 and CFB in tumor cells in cSCCs in vivo. In
addition, staining for C3 was noted on cSCC cell surface in
tumors in vivo (Figure 2). Immunostaining for C3 was
moderate or strong in most cSCCs and in an aggressive form
of cSCC, RDEBSCC, staining for C3 was mainly strong.
No tumors with negative staining for C3 were detected in
cSCC or in RDEBSCC groups, whereas in premalignant
lesions, actinic keratosis (AK) and in situ tumors (cSCCIS),The American Journal of Pathology - ajp.amjpathol.orgweak or negative staining was noted. In normal intact skin,
staining for C3 was negative in almost half of the cases.
Similarly, staining for CFB was stronger in cSCC tumors
compared to cSCCISs, AK, and normal skin (Figure 3). In
almost all RDEBSCC samples, staining for CFB was strong,
and in most cases in cSCC group, staining was strong or
moderate. No negative staining for CFB was noted in any
cSCC or RDEBSCC tissue sample. Only few samples of
AK and cSCCIS stained strongly for CFB, and most stained
weakly or were negative. Most normal skin samples were
also negative for CFB. In summary, the results of IHC
staining suggest C3 and CFB as biomarkers for develop-
ment of cSCC to the invasive stage.
Additional evidence for the roles of C3 and CFB in
cutaneous carcinogenesis was obtained with examination of
chemically induced mouse cSCCs. The results showed that
the mean expression levels of C3 and CFB mRNAs were1195
Riihilä et alhigher in mouse cSCCs than in papillomas, TPA-treated
hyperplastic skin, or normal skin (Figure 4). Together, these
observations show that the expression of C3 and CFB is
signiﬁcantly up-regulated in invasive cSCCs in vivo, sug-
gesting roles for them in the growth of cSCC. Our ﬁndings
are supported by previous observations showing expression
of C3 and CFB by tumor cells in rhabdomyosarcoma27,28
and glioma29 and CFB in pancreatic ductal adenocarci-
noma.30 C3 has been suggested as a prognostic factor in
nonesmall-cell lung cancer.31 In ovarian cancer, high C3 or
C5R mRNA levels were associated with reduced survival
and were suggested as tumor-derived complement proteins
promoting tumor growth.32
In Ha-rasetransformed HaCaT cell lines representing
different stages of keratinocyte carcinogenesis,19 the
expression of C3 and CFB was associated with the tumor-
igenic potential (Figure 5A). The basal expression of C3 and
CFB was low in parental HaCaT cells and in benign
tumorigenic Ha-rasetransformed HaCaT cell line (A5). In
contrast, the expression of C3 and CFB was clearly higher
in the tumorigenic cell line II-4 and in the most aggressive
invasive tumorigenic cell line RT3. These ﬁndings reveal
that the basal expression of C3 and CFB is not induced
by p53 inactivation or ras-transformation alone, but that
other mechanisms are obviously required. Our results also
show that the level of C3 expression is enhanced by IFN-g
in cSCC cells and that the basal CFB expression is up-
regulated by both IFN-g and TNF-a in cSCC cells
(Figure 5B). In previous studies, IFN-g has been shown to
up-regulate C3 and CFB expression and TNF-a to up-
regulate C3 expression in keratinocytes.10 These results
show that C3 and CFB expression by cSCC cells is sus-
ceptible to regulation by inﬂammatory cytokines present in
the tumor microenvironment of cSCCs.
Silencing of C3 and CFB expression in cSCC cells
revealed that both C3 and CFB promote proliferation and
migration of cSCC cells (Figure 6). Additional functional
in vivo studies using xenograft model of human cSCC in
SCID mice showed that knockdown of C3 or CFB resulted
in signiﬁcant delay in cSCC xenograft growth and in
reduction in the number of proliferating cells in the tumors
(Figures 7 and 8). These observations are in accordance
with our ﬁnding that knockdown of C3 and CFB potently
inhibited activation of ERK1/2 and proliferation of cSCC
cells (Figure 6). C3 cleavage product C3a has been shown
to activate mitogenic signaling pathways (phosphatidyli-
nositol 3-kinase/AKT), activate cell cycle, and increase
production of TNF-a, transforming growth factor-b, and
IL-6.32 In addition, CFB activation fragment Bb is a serine
proteinase and it is therefore possible that CFB may exert
additional functions in cSCC growth beyond complement
system activation. In summary, these results provide
evidence for the roles of C3 and CFB in cSCC growth
in vivo.
Recently, the indirect effects of complement system on
tumor growth by altering the host immunoresponse have1196been emphasized.6,33,34 UV radiation and immunosuppres-
sion are important risk factors for initiation and develop-
ment of cSCC. UV radiation has been shown to exert an
immunosuppressive effect in skin, and CFB has recently
been identiﬁed as an important mediator of UVA- and
UVB-induced immunosuppression.35 CFB may serve as a
molecular link between UV-induced immunosuppression in
skin and development cSCC. Chronic inﬂammation is also a
risk factor for cSCC, and complement activation has been
shown to promote colitis-associated carcinogenesis through
activation of IL-1b.36 Complement activation releases ana-
phylatoxins C3a and C5a, both of which may modulate
tumor microenvironment by serving as chemotaxins and
promoting generation of radical oxygen species, by
increasing vascular permeability, and by increasing hista-
mine release from mast cells.37
In summary, the results of this study show that comple-
ment system components C3 and CFB are overexpressed by
tumor cells in cSCC in vivo, suggesting that these compo-
nents play important roles in cSCC growth. In addition, our
results show that C3 and CFB regulate proliferation
and migration of cSCC cells and promote growth of cSCC
xenografts in vivo. These results identify C3 and CFB as
tumor celleassociated molecular markers for development
of cSCC and suggest them as potential therapeutic targets in
recurrent and metastatic cSCCs.
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